Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or refractory multiple myeloma have earned the company the third ultra-spe | FDA ...

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro), both from Janssen Biotech, Inc, marks a significant shift in treating ...

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future. Recently, the U.S. Food and Drug Administration (FDA) accepted a new drug ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Natco Pharma launched a cheaper generic version of the cancer drug ‘Pomalyst’ in the U.S. to treat multiple myeloma, making ...

For Julie Cohen, a diagnosis of multiple myeloma wasn't just a medical hurdle — it was a profound shift in perspective. Initially searching for a cure, she soon realized that navigating a high-risk, ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, next-generation trispecific antibodies are yielding high response rates in ...

Anemia often goes hand-in-hand with multiple myeloma. Sometimes, the cancer causes the anemia. And sometimes, the cancer treatment does. But it's possible to resolve it and feel better. (Photo Credit: ...

This reinforces the need for a CV assessment and surveillance before, during, and after the therapy, a researcher says.